Adiponectin restrains ILC2 activation by AMPK-mediated feedback inhibition of IL-33 signaling

Lu Wang1,2,3*, Yan Luo2,4, Liping Luo4,5, Dandan Wu6,8, Xiaofeng Ding1,6, Handong Zheng4,6, Haisha Wu1,6, Bilian Liu7,6, Xin Yang2,6, Floyd Silva1,6, Chunqing Wang1,6, Xing Zhang1,6, Xianyun Zheng1,6, Jingdong Chen1,6, Jonathan Brigman6,5, Michael Mandell4,5, Zhiguang Zhou1,6, Feng Liu7,6, Xuexian O. Yang4,5, and Meilian Liu2,4,6

ILC2s are present in adipose tissue and play a critical role in regulating adipose thermogenesis. However, the mechanisms underlying the activation of adipose-resident ILC2s remain poorly defined. Here, we show that IL-33, a potent ILC2 activator, stimulates phosphorylation of AMPK at Thr172 via TAK1 in primary ILC2s, which provides a feedback mechanism to inhibit IL-33–induced NF-κB activation and IL-13 production. Treating ILC2s with adiponectin or an adiponectin receptor agonist (AdipoRon) activated AMPK and decreased IL-33–NF-κB signaling. AdipoRon also suppressed cold-induced thermogenic gene expression and energy expenditure in vivo. In contrast, adiponectin deficiency increased the ILC2 fraction and activation, leading to up-regulated thermogenic gene expression in adipose tissue of cold-exposed mice. ILC2 deficiency or blocking ILC2 function by neutralization of the IL-33 receptor with anti-ST2 diminished the suppressive effect of adiponectin on cold-induced adipose thermogenesis and energy expenditure. Taken together, our study reveals that adiponectin is a negative regulator of ILC2 function in adipose tissue via AMPK-mediated negative regulation of IL-33 signaling.

Introduction

Beige or brite adipocytes, which are enriched in subcutaneous fat such as inguinal fat, have high thermogenic capacity and have become a new therapeutic target for the treatment of obesity (Boström et al., 2012; Fisher et al., 2012; Petrovic et al., 2010). Group 2 innate lymphoid cells (ILC2s) were first discovered in the lymphoid structure associated with adipose tissues in the peritoneal cavity (Moro et al., 2010) and are activated by the epithelial cell–derived cytokines IL-33 and IL-25, as well as thymic stromal lymphopoietin, in response to allergens (Cayrol and Girard, 2014; Koyasu and Moro, 2013; Licona-Limón et al., 2013). It was recently shown that ILC2s are present in murine and human adipose tissue and play a critical role in regulating beige adipocyte development, referred to as browning of white adipose tissue (WAT), by producing the opioid peptide methionine-enkephalin (Penk) and the type 2 cytokines IL-5 and IL-13 (Moro et al., 2010; Lee et al., 2015; Brestoff et al., 2015). Moreover, decreased ILC2 population and response in adipose tissue were considered as conserved characteristics of obesity and its related diseases, such as atherosclerosis (Brestoff et al., 2015; Lee et al., 2015; Newland et al., 2017; Ding et al., 2016). In contrast, activation of ILC2s promotes WAT browning and acts to prevent obesity (Brestoff et al., 2015; Lee et al., 2015). However, how adipose-resident ILC2s are recruited and regulated is poorly understood.

IL-33 plays an essential role in the activation of ILC2s in adipose tissue, as well as in the lung and intestine (Brestoff et al., 2015; Lee et al., 2015). Adipose tissue contains relatively high amounts of IL-33 compared with the lung and spleen (Miller et al., 2010; Vasanthakumar et al., 2015; Zeyda et al., 2013). Multiple types of adipose tissue–dressing cells, including endothelial cells, fibroblasts, and adipocytes themselves, produce IL-33 (Molofsky et al., 2015; Odegaard et al., 2016; Li et al., 2018). As a member of the IL-1 family, IL-33 binds to the IL-1 receptor–related protein ST2 coupling an IL-1RAcP (IL-1 receptor accessory

1Department of Biochemistry and Molecular Biology, University of New Mexico Health Sciences Center, Albuquerque, NM; 2Department of Endocrinology and Metabolism, National Clinical Research Center for Metabolic Diseases, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Central South University, Changsha, Hunan, China; 3Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; 4Department of Microbiology and Molecular Genetics, University of New Mexico Health Sciences Center, Albuquerque, NM; 5Autophagy, Inflammation and Metabolism Center for Biomedical Research Excellence, University of New Mexico Health Sciences Center, Albuquerque, NM; 6Department of Neuroscience, University of New Mexico Health Sciences Center, Albuquerque, NM; 7Department of Pharmacology, University of Texas Health at San Antonio, San Antonio, TX.

© 2020 Wang et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.nupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
protein) unit, by which it promotes TGFβ-activated kinase 1 (TAK1) binding to TNF-receptor–associated factor 6 (TRAF6) and activates the canonical IkB kinases (IKKs) IKKa and IKKβ, leading to the phosphorylation and degradation of IkB, releasing NF-κB (Cao et al., 1996; Takaesu et al., 2000; Wang et al., 2001). Activated NF-κB promotes transcription of GATA binding protein 3 (GATA3), ST2, and consequently IL-5 and IL-13, leading to the activation of ILC2s and the type 2 immune response (Ali et al., 2011; Lloyd, 2010; Guo et al., 2012; Lee et al., 2015; Brestoff et al., 2015). Hypoxia-inducible factor α was recently found to suppress ST2 expression and ILC2 function by regulating the glycolytic enzyme pyruvate kinase M2 (Li et al., 2018). In addition, IL-33 was shown to induce the ILC2 function via the intercellular cell adhesion molecule 1 (ICAM-1)–mediated activation of ERK1/2 that stabilizes GATA3 (Lei et al., 2018). However, the feedback regulation of IL-33 signaling to control ILC2 activation remains largely unknown.

The energy sensor AMP-activated protein kinase (AMPK) is activated by a deficit in nutrients and stimulates cellular metabolic pathways such as glucose uptake and fatty acid oxidation (Long and Zierath, 2006). AMPK is a heterotrimeric protein and consists of a catalytic α subunit and regulatory β and γ subunits (Hardie, 2004; Carling, 2004; Long and Zierath, 2006). Each α, β, and γ subunit is encoded by its own genes (α1 and α2, β1 and β2, or γ1, γ2 and γ3, respectively; Hardie, 2004; Carling, 2004; Long and Zierath, 2006). The elevation of intracellular levels of AMP, as well as an increased ratio of AMP to ATP, due to nutrient deprivation activates AMPK allosterically, inducing phosphorylation of AMPK at Thr172, within the activation domain of the α subunit, by liver kinase 1 (LKB1; Hardie, 2004; Carling, 2004; Long and Zierath, 2006).

AMPK is also activated by calcium/calmodulin–dependent protein kinase (CaMKK) when the intracellular Ca2+ level is elevated (Woods et al., 2005; Hawley et al., 2005). While it has been well established that AMPK controls systemic energy and glucose homeostasis in skeletal muscle, liver, adipose tissues, and pancreatic β cells, all of which are insulin-target or producing tissues (Hardie, 2004; Carling, 2004; Long and Zierath, 2006), little is known about whether AMPK also plays an important role in immune responses. Very recently, Blagih et al. (2015) showed that AMPK is a key regulator of T cell bioenergetics and viability and subsequent T cell–mediated adaptive immunity. Whether AMPK is critical for the activation and function of ILC2s remains elusive.

In the present study, we observed that AMPK is activated upon IL-33 treatment, and feedback inhibits IL-33–stimulated phosphorylation of IKKa/β and IkBα in ILC2s. Adiponectin treatment, via synergistic activation of AMPK, inhibits the IL-33–stimulated NF-κB pathway and IL-13 production in ILC2s. Adiponectin deficiency enhanced cold-induced thermogenic gene expression and energy expenditure, which was associated with decreased ILC2 apoptosis and increased cytokine production by ILC2s; the antithermogenic effects of adiponectin were diminished by ILC2 deficiency or blocking ILC2 function. These results demonstrate that adiponectin plays a critical role in regulating ILC2s and energy expenditure through an AMPK-dependent negative regulation of IL-33 signaling, a potential adverse effect of adiponectin-based therapeutics.

Results

Adiponectin inhibits IL-33 signaling via an AMPK-dependent mechanism in ILC2s

We recently showed that leptin, an adipokine, promotes proliferation and survival of proallergic ILC2s and production of type 2 cytokines in the lung (Zheng et al., 2018; Zheng et al., 2016). We asked if adiponectin, the most abundant adipokine, is involved in the regulation of ILC2 function and whether adiponectin–ILC2 communication (if it exists) occurs in the local adipose tissue. Using flow cytometry, we found that both adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2) were present in ILC2s, as well as in macrophages and adipocytes (Fig. 1 A and Fig. S1 A). As expected, treatment with 5 µg/ml adiponectin stimulated phosphorylation of AMPK at Thr172 in adipose-resident ILC2s (Fig. 1 B). Surprisingly, adiponectin treatment suppressed IL-33–induced production of IL-13 in the stromal vascular fraction (SVF) of WAT (Fig. 1 C). Consistent with this, treatment of adiponectin also suppressed IL-33–induced production of IL-13 in primary ILC2s (Fig. 1 D), suggesting an inhibitory effect of adiponectin on IL-33–stimulated ILC2 activation. In support of this, treatment with 10 µM adiponectin receptor agonist (AdipoRon) suppressed IL-33–induced phosphorylation of IKKa/β at Ser276/280 and IkBα at Ser232/236, two well-known kinases in NF-κB signaling, in ILC2s (Fig. 1 E and F). In addition, IL-33 activated AMPK, as indicated by the phosphorylation of acetyl-coenzyme A (acyetyl-CoA) carboxylase, whereas AdipoRon treatment further enhanced AMPK activation and suppressed IL-33–stimulated phosphorylation of IKKa/β in primary differentiated type 2 helper T cells (Th2 cells; Fig. 1 G), a lymphoid cell type closely related to ILC2s with the ability to produce the type 2 cytokines IL-5 and IL-13 (Zhu, 2015). However, the suppressive effects of AdipoRon on phosphorylation of IKKa/β were attenuated by knockdown of AMPK in Th2 cells (Fig. 1 H). These results suggest that adiponectin inhibits ILC2 function via AMPK activation.

AMPK is activated by IL-33, and feedback inhibits IL-33–induced NF-κB signaling

To dissect the role of AMPK in IL-33 signaling, we treated primary Th2 cells with 10 ng/ml IL-33 at various time points. We found that IL-33 treatment stimulated phosphorylation of AMPK as well as IKKa/β (Fig. 2 A). IL-33 treatment also stimulated the phosphorylation of Unc-51-like autophagy-activating kinase 1 (ULK1) at Ser177 (Fig. 2 A), a site that is phosphorylated following AMPK activation. In addition, the phosphorylation of AMPK and IKKa/β occurred at 5 min and reached its peak at ~10 min upon IL-33 treatment (Fig. 2 A). Consistent with this, IL-33 treatment for 10 min stimulated phosphorylation of AMPK in adipose-resident ILC2s (Fig. 2 B), suggesting the activation of AMPK by IL-33 in ILC2s. To determine whether AMPK plays a role in regulating ILC2 function, we cotreated isolated ILC2s with IL-33 and compound C, an AMPK–specific inhibitor. Inhibiting AMPK enhanced IL-33–stimulated phosphorylation of IKKa/β in...
Adiponectin inhibits IL-33 signaling in an AMPK-dependent manner in ILC2s. Adipose-resident ILC2s were isolated from SVFs of WAT and cultured in a fresh RPMI medium with 1% FBS for 1 h for the following studies (A–F). (A) AdipoR1 and AdipoR2 were expressed in adipose-resident ILC2s. Two mice were used for each independent experiment. Representative data are presented from two independent experiments. (B) Adiponectin treatment stimulated AMPK phosphorylation in primary ILC2s. Starved cells were treated with 5 µg/ml full-length adiponectin for 20 min followed by flow cytometry analysis. ADPN, adiponectin. Three to six mice were used for each independent experiment. Data are shown as means ± SEM. *, P < 0.05, Student’s t test. Each experiment was conducted three times independently. (C) Adiponectin treatment decreased the release of IL-13 induced by IL-33 in adipose SVF. SVFs were cultured in the medium containing 10% FBS and treated with 5 µg/ml full-length adiponectin for 1 h, followed by treatment with 10 ng/ml IL-33 for 18 h. The medium was collected for ELISA analysis. ADPN, adiponectin. Three to six mice were used for each independent experiment. Data are presented as means ± SEM. *, P < 0.05, Student’s t test. Each experiment was conducted three times independently. (D) Adiponectin treatment suppressed IL-33-induced IL-13 production in primary ILC2s. ILC2s were treated as described in C. Three to six mice were used for each independent experiment. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01, Student’s t test. Each experiment was conducted three times independently. (E and F) Treatment with 10 µM AdipoRon suppressed IL-33–stimulated phosphorylation of IKKα/β (E) and IκBα (F). Starved ILC2s were treated with 10 µM AdipoRon for 1 h, followed by treatment with 10 ng/ml IL-33 for 10 min and flow cytometry analysis. Four to six mice were used for each independent experiment. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01, Student’s t test. Each experiment was conducted three times independently. (G) AdipoRon treatment suppressed IL-33–stimulated phosphorylation of IKKα/β in Th2 cells. One mouse was used for each independent experiment. Representative data are presented from three independent experiments. ACC, acetyl-CoA carboxylase; p-ACC, phosphorylation of acetyl-CoA carboxylase. (H) Suppressing AMPK by siRNA diminished the inhibitory effect of AdipoRon on IL-33–stimulated phosphorylation of IκBα/β in Th2 cells. Two mice were used for each independent experiment. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01; Student’s t test. Each experiment was conducted three times independently. Ctrl, control; MFI, mean fluorescence intensity; No Ab, without treatment of antibodies; P, phosphorylation.

Suppressing TAK1 diminished IL-33 signaling in an AMPK-dependent manner in ILC2s. Two mice were used for each independent experiment. Representative data are presented from two independent experiments. (B) Adiponectin treatment stimulated AMPK phosphorylation in primary ILC2s. Starved cells were treated with 5 µg/ml full-length adiponectin for 20 min followed by flow cytometry analysis. ADPN, adiponectin. Three to six mice were used for each independent experiment. Data are shown as means ± SEM. *, P < 0.05, Student’s t test. Each experiment was conducted three times independently.
Adiponectin inhibits ILC2 function

Wang et al.

Adiponectin inhibits ILC2 function

in iWAT without significant effects on the macrophage marker F4/80 or the glucocorticoid receptor Nr3c1 (Fig. 3 D). In addition, adiponectin deficiency suppressed apoptosis of ILC2s despite no significant effect on proliferation (Figs. 3 E and Fig. S1 F). The inhibitory effect of adiponectin on ILC2 and Th2 cells was supported by the evidence of aggravated allergic asthma-stimulated ILC2/Th2 cell activation and type 2 immune response in the airways of adiponectin KO mice (Fig. S1, G–M).

Adiponectin deficiency enhances cold-induced thermogenesis and energy expenditure

Given the promoting effect of ILC2 on thermogenesis (Lee et al., 2015; Brestoff et al., 2015), we performed indirect calorimetry...
experiments in adiponectin KO mice. 10-wk-old male adiponectin KO and WT littermates were housed individually in the metabolic phenotyping system coupled with an environmental chamber. Adiponectin KO mice displayed slightly increased room temperature O2 consumption throughout the light and dark cycle compared with WT littermates despite no significant differences in body mass, lean mass, fat mass, food intake, respiratory quotient, or beam-break counts (Fig. 4 A; and Fig. S2, A–D). This effect became more pronounced when the mice were exposed to both acute cold (6°C, for 48 h; Fig. 4 A) and chronic cold (6°C, for 6 d; Fig. 4 A). Consistently, adiponectin KO mice exhibited increased protein levels of the thermogenic markers UCP1, C/EBPβ, and PGC1α and mRNA levels of UCP1 and PGC1α in iWAT and BAT (Fig. 4, B–E; and Fig. S1 E). Furthermore, adiponectin deficiency protected mice from the cold stress-induced decline of core body temperature, with little effect on locomotor activity (Fig. 4 F and Fig. S2 E). Together, the results from our study suggest that adiponectin exerts an antithermogenic effect.

**Administration of AdipoRon inhibits ILC2 activation and cold-induced thermogenesis in adiponectin KO mice**

To determine if adiponectin deficiency is the primary cause of increased energy expenditure and thermogenesis in adiponectin KO mice, we administered an adiponectin receptor agonist, AdipoRon, by i.p. injection to 10-wk-old adiponectin KO mice (Okada-Iwabu et al., 2013). AdipoRon administration for 5 d significantly decreased O2 consumption while having little effect on food intake and activity under basal and cold stress conditions (Fig. 5 A; and Fig. S2, F and G). Moreover, the thermogenic markers UCP1, C/EBPβ, and PGC1α were suppressed by AdipoRon administration in iWAT, whereas the suppressive effects of AdipoRon in BAT were not significant (Fig. 5, B and C). In addition, the frequencies of ILC2s and M2 macrophages in iWAT were decreased by AdipoRon treatment under cold...
conditions (Fig. 5, D and E). In support of this, AdipoRon treatment decreased the fraction of eosinophils and total macrophages in iWAT, although the difference did not reach significance (Fig. S2, H and I). AdipoRon treatment also decreased the frequency of ILC2s and M2 macrophages in eWAT, while the difference did not reach significance accompanied with little effect on BAT (Fig. 5, D and E). However, intracerebroventricular (i.c.v.) administration of trimeric adiponectin had no significant effect on energy expenditure, food intake, and activity (Fig. S2, J–L) or UCP1 expression in either BAT or iWAT (data not shown), indicating that the suppressive effect of adiponectin on cold adaptation is mediated at the level of periphery. In agreement with this, intra-iWAT injection of AdipoRon significantly suppressed cold-induced UCP1 expression.
Adiponectin inhibits cold-induced thermogenesis via ILC2-dependent mechanisms

To investigate if adiponectin suppresses adipose thermogenesis through regulating ILC2s, 10-wk-old adiponectin KO mice were administered ST2 antibody to neutralize IL-33 action as described (Fig. 6 A). Flow cytometry data show that administration of ST2/IL-1 R4 antibody significantly suppressed the fraction of ILC2s (Fig. 6 B). In addition, despite minor effects at room temperature, blocking ILC2 function diminished the increase of cold-induced O2 consumption and up-regulation of the thermogenic genes Ucp1, C/EBPβ, and Pgc1α in iWAT in adiponectin KO mice under cold conditions (Fig. 6, C–E). Inhibiting ILC2 function, on the other hand, had little effect on food intake and activity (Fig. S2, M and N). Rag2/IL2rg double-KO mice were known to lack ILC2s, and Rag2 KO mice were considered as ILC2-sufficient mice in previous studies (Brestoff et al., 2015). ILC2-deficient and sufficient mice were administered with AdipoRon. We observed that ILC2 deficiency diminished AdipoRon suppression of O2 consumption and thermogenic gene expression in iWAT under both room temperature and cold stress conditions, indicating the mediatory role of ILC2s in adiponectin suppression of energy expenditure (Fig. 6, F and G). Moreover, the inhibitory effect of adiponectin on IL-4 and IL-13 production in the SVF was alleviated by ILC2 deficiency (Fig. 6, Hand I), suggesting that adiponectin suppresses type 2 immune response and thermogenesis via ILC2-dependent mechanisms. However, the role of adiponectin in the regulation of energy homeostasis and thermogenesis remains controversial in the field (Qi et al., 2004; Hui et al., 2015; Bauche et al., 2007; Masaki et al., 2003; Holland et al., 2013; Kubota et al., 2007; Kajimura et al., 2013; Qiao et al., 2014; Kim et al., 2007; Saito et al., 2006; Quaresma et al., 2016). To further address the controversy about
whether adiponectin exerts an antithermogenic effect, we
ordered an additional mouse strain, in which adiponectin is also
deficient, from Jackson Laboratory (B6;129-Adipoqtm1Chan/J,
stock no. 008195; Adipo-; Ma et al., 2002). The mouse model
from Jackson Laboratory has a B6;129 background, while the
model used in the present study has a C57BL/6J background.
Because the genetic background of strains has a considerable
impact on the metabolic phenotype (Hummel et al., 1972;
Coleman and Hummel, 1973; Mao et al., 2006a; Fontaine and
Davis, 2016), we backcrossed an adiponectin KO mouse model
from Jackson Laboratory with C57BL/6J mice for four gen-
erations. As expected, adiponectin expression level was not
detected in the KO mice, while it was highly enriched in adipose
tissue of WT mice (Fig. S3, D and E). Using the same metabolic

Figure 6. Adiponectin negatively regulates thermogenesis via ILC2-dependent mechanisms. (A) A time frame for administration of ST2 antibody in adiponectin KO and control mice. (B) Administration of ST2 antibody suppressed adiponectin deficiency–increased ILC2 fraction in iWAT and eWAT despite minor effects in BAT. n = 5–6/group. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01; Student’s t test. (C and D) Blocking ILC2 function with ST2 antibody decreased adiponectin deficiency–increased O2 consumption (C) and expression levels of thermogenic genes Ucp1, C/ebpβ, and Pgc1α (D) under cold stress conditions. n = 5–6/group. Data are presented as means ± SEM. *, P < 0.05; Student’s t test. (C and D) Blocking ILC2 function with ST2 antibody decreased adiponectin deficiency–increased O2 consumption (C) and expression levels of thermogenic genes Ucp1, C/ebpβ, and Pgc1α (D) under cold stress conditions. n = 5–6/group. Data are presented as means ± SEM. *, P < 0.05; Student’s t test. (E) Expression levels of UCP1, C/EBPβ, and PGC1α in D were quantified and analyzed, and tubulin was used as a loading control. n = 5–6/group. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01. Student’s t test. (F and G) The inhibitory effect of AdipoRon on O2 consumption (F) and thermogenic gene expression in iWAT (G) was reversed by ILC2 deficiency. n = 6–9/group. Data are shown as means ± SEM. *, P < 0.05; Student’s t test. (H and I) The secretion of IL-4 (H) and IL-13 (I) was enhanced by IL-33 and decreased by adiponectin treatment in the SVF of iWAT. SVF was cultured in FBS-free medium containing 0.5% BSA and then treated with or without 5 µg/ml adiponectin for 1 h, followed by treatment with or without 10 ng/ml IL-33 for 18 h using two mice for each independent experiment. Data are presented as means ± SEM. *, P < 0.05; Student’s t test. Each experiment was conducted three times independently. ADPN, adiponectin; ST2, ST2 antibody; V and Veh, vehicle.
phosphorylation. A study by Kolodina et al. (2009) showed that AMPK is activated by cold exposure in mammalian cell lines (22°C or 37°C for 24 h) and that AMPK activation is associated with the transcriptional induction of thermogenin (Kim et al., 2014). The activation of AMPK by cold exposure is mediated by the induction of PGC-1α, which is a key transcriptional activator of thermogenesis (Yoshida et al., 2004). In addition, AMPK is activated by the phosphorylation of Thr172 by the kinase LKB1, which is upstream of AMPK in the signaling cascade (Maiuri et al., 2007). This activation of AMPK by cold stress is important for the upregulation of thermogenic gene expression in BAT (Antonia and Baldwin, 2018).

**Cold stress suppresses expression levels and circulation levels of adiponectin in mice**

Next, we investigated whether expression and circulating levels of adiponectin are affected by cold stress. 3-mo-old male C57BL/6 mice were housed in an environmental chamber either at 22°C or 6°C for 48 h. Cold exposure induced expression of UCP1 but down-regulated adiponectin expression in BAT and iWAT (Fig. 7, A and B), as well as circulating levels, in vivo (Fig. 7 C). Consistent with other recent studies (Hui et al., 2015; Dong et al., 2013), the circulating levels of adiponectin were also down-regulated by chronic cold stress (6°C, 6 d; Fig. 7 D), suggesting that adiponectin levels are negatively correlated with thermogenesis. Moreover, mRNA levels of adiponectin were suppressed by 2-d and 6-d cold stress in iWAT (Fig. 7, E and F). These results suggest that the levels of adiponectin in adipose tissue and in circulation are associated with cold adaptation.

**Discussion**

ILC2s were recently shown to be present in adipose tissue and play a critical role in regulating browning of WAT by promoting IL-4/IL-13-driven type 2 immunity or increasing the ILC2-derived cytokine Penk (Lee et al., 2015; Brestoff et al., 2015). Moreover, increased ILC2 response limits the development of obesity (Lee et al., 2015; Brestoff et al., 2015). However, the mechanisms underlying the activation of adipose-resident ILC2s remain largely unknown. Our present study shows that AMPK is downstream of IL-33 signaling and that feedback inhibits IL-33-induced activation of NF-κB and production of IL-13 in adipose-resident ILC2s. In addition, adiponectin suppresses cold-induced ILC2 activation through AMPK-mediated feedback inhibition of IL-33 signaling and subsequently suppresses thermogenic gene expression in adipose tissue and energy expenditure. Our results reveal a new mechanism underlying ILC2 activation and subsequent WAT browning in response to cold stress and also provides new insight into the proadipogenic effects of adiponectin.

IL-33 is an activator of ILC2s and plays a pivotal role in regulating metabolism (Lee et al., 2015; Brestoff et al., 2015). Moreover, a shorter, soluble version of IL-33 also has a direct impact on adipocytes by splicing UCp1 transcripts in the nucleus and regulating thermogenesis (Odegaard et al., 2016). IL-33 appears to be produced in adipose tissue, where fibroblasts are the main IL-33-producing cells (Kolodin et al., 2015; Kuswanto et al., 2016). Our laboratory and others have shown that IL-33 is associated with cold adaptation and obesity development (Odegaard et al., 2016; Ding et al., 2016). However, little is known about the regulation of IL-33 signaling in ILC2s. We show that similar to IKKα/β, IL-33–stimulated AMPK is also inhibited by suppressing TAK1 in ILC2s (Fig. 2), indicating that TAK1 mediates IL-33–stimulated AMPK activation in ILC2s. In agreement with this, TAK1 was identified as a potential upstream kinase of the budding yeast orthologue of AMPK (the SNF1 complex) in yeast and phosphorylates Thr172, activating AMPK in vitro (Momcilovic et al., 2006). In addition, TAK1 also mediates AMPK activation in response to various stimuli, including TNF-related apoptosis-inducing ligand, hydrogen peroxide, IL-1β, TNFα, and bacterial infection in epithelial cells and cardiomyocytes (Herrero-Martín et al., 2009; Chen et al., 2013; Liu et al., 2018; Xie et al., 2006; Antonia and Baldwin, 2018).
Activation of AMPK by TNF-related apoptosis-inducing ligand requires TAK1, but not LKB1 and CaMKK-β, the known upstream kinases for AMPK activation under conditions such as glucose starvation and calcium ionophore (Herrero-Martin et al., 2009; Xie et al., 2006). In support of this, our data suggest that TAK1 is required for IL-33–stimulated AMPK in ILC2s. Furthermore, Antonia and Baldwin (2018) showed that IKK directly phosphorylates AMPK at Thr172 when its own Thr223 is phosphorylated by TAK1, upon treatment of IL-1β or TNF-α in cancer cells. Which kinase, TAK1 or IKK, catalyzes phosphorylation of AMPK may stem from the difference in cell types or stimuli. On the other hand, although IL-33 is a potent activator of ILC2, it may display opposite functions in ILC2s under various physiological conditions. Of note, IL-33 up-regulates PD-1 expression and intrinsically negatively regulates production of IL-5 and IL-13 on ILC2s in obese mice (Oldenhove et al., 2018). Given that TNF-α-mediated M1 macrophage polarization is required for ILC2 dysfunction in obesity (Oldenhove et al., 2018), IL-33 up-regulation itself may not be sufficient to promote development as well as activation of ILC2 in adipose tissue under obese conditions.

AMPK activation provides a negative regulatory mechanism in IL-33 signaling in ILC2s and Th2 cells. Inhibiting or suppressing AMPK increases IL-33–induced ILC2 activation by enhancing the NF-κB pathway and secretion of IL-13 (Fig. 2). In support of this, both AdipoR1 and AdipoR2 are expressed in primary ILC2s, and adiponectin signaling suppressed the IL-33–stimulated NF-κB pathway in both Th2 cells and ILC2s (Fig. 1). This is also supported by the finding that adiponectin has been shown to inactive NF-κB in other cell types (Ajuwon and Spurlock, 2005). We show that AMPK, a well-known effector of adiponectin signaling (Petrovic et al., 2010; Yamauchi et al., 2002; Wu et al., 2003; Mao et al., 2006b; Ruan and Dong, 2016), is critical for the inhibitory effect of adiponectin on IL-33–induced activation of IKK and IL-13 production in ILC2s, providing new insight into adiponectin inhibition of ILC2 function. However, how AMPK signaling inhibits NF-κB pathway in ILC2s remains poorly understood. Following AMPK activation, phosphorylation of ULK1 at Ser321, an activation site of ULK1 and a marker of autophagy initiation, occurs in response to IL-33 treatment (Fig. 2 A). It is possible that AMPK/autophagy pathway inactivates NF-κB through regulating P62, given that P62 has been suggested to promote NF-κB through multiple mechanisms: increasing the phosphorylation of IKKβ by binding to atypical PKCs, activation of polyubiquitination of TRAF6, and promoting ROS-induced RAS expression (Lallen et al., 1999; Martin et al., 2006; Wooten et al., 2005; Duran et al., 2008). Future studies will be needed to clarify this possibility.

Adiponectin exerts antidiabetic effects (Ahima, 2006; Scherer, 2006; Kadowaki and Yamauchi, 2005; Kuswanto et al., 2016; Nawrocki et al., 2006), and its expression and circulating levels are down-regulated by obesity in human subjects (Scherer et al., 1995; Abbasi et al., 2004). However, the role of adiponectin in the regulation of energy homeostasis and thermogenesis remains controversial. Several studies show that adiponectin promotes energy expenditure and the cold-induced browning effect through its central and peripheral actions (Qi et al., 2004; Hui et al., 2015; Bauche et al., 2007; Masaki et al., 2003; Holland et al., 2013). However, other studies have suggested that adiponectin may be a negative regulator of energy expenditure and thermogenesis (Kubota et al., 2007; Kajimura et al., 2013; Qiao et al., 2014; Kim et al., 2007; Saito et al., 2006; Quaresma et al., 2016). These inconsistent observations highlight the need for research identifying the true physiological functions and underlying mechanisms of adiponectin in the regulation of energy metabolism. In addition, there is also a controversy as to whether adiponectin acts as an anti- or proinflammatory mediator (Maeda et al., 2002; Xu et al., 2003; Kumada et al., 2004; Ohashi et al., 2010; Tsao et al., 2002; Cheng et al., 2012; Park et al., 2007; Awazawa et al., 2011; Tang et al., 2007; Ding et al., 2016). More importantly, it remains largely unknown whether adiponectin regulates thermogenesis and energy expenditure through an inflammatory response, which is a key factor of WAT browning (Molofsky et al., 2013; Lee et al., 2015; Qiu et al., 2014; Rao et al., 2014). By using adiponectin KO mice, Hui et al. (2015) found that adiponectin promotes WAT browning by direct stimulation of M2 macrophage proliferation, with little effect on ILC2s. This mouse model was shown to display a rather moderate phenotype in insulin sensitivity (Ma et al., 2002). By using the adiponectin KO mice that displayed magnified insulin resistance compared with the controls, when dietarily challenged (Nawrocki et al., 2006), we found that adiponectin plays an inhibitory role in regulating adipose-resident ILC2s, type 2 immunity, and energy expenditure (Figs. 2, 3, 4, and 5), suggesting that the inhibitory effect of adiponectin on thermogenesis may explain its proadipogenic properties.

To validate if adiponectin exerts antithermogenic effects, we ordered another adiponectin KO mouse strain from Jackson Laboratory and backcrossed this strain of adiponectin-deficient mice with C57BL/6 for four generations. The results also demonstrate that adiponectin acts as a negative regulator of ILC2s as well as thermogenesis in adipose tissue (Fig. S3). Using the same metabolic phenotyping system, we were the first to characterize two adiponectin KO mouse strains and show that adiponectin suppresses ILC2 function and thermogenesis. In support of this, Kajimura et al. (2013) generated one more adiponectin KO mouse model with a mixed background of C57BL/6J and 129/Sv and showed that adiponectin deficiency enhanced energy expenditure through the central nervous system. In contrast, administration of adiponectin receptor agonist AdipoRon reverses the increase in ILC2 population as well as energy expenditure in adiponectin KO mice under cold stress conditions (Fig. 5). Collectively, adiponectin-based therapeutics may bring potential side effects such as antithermogenic and pro-obesity effects.

On the other hand, it was recently challenged whether alternatively activated macrophages synthetize catecholamine or contribute to thermogenesis and energy homeostasis (Fischer et al., 2017). In addition, there is also a controversy regarding whether IL-4–IL-13 signaling plays an essential role in catecholamine production and thermogenesis (Fischer et al., 2017; Molofsky et al., 2013; Rao et al., 2014; Brestoff et al., 2015). Therefore, it remains unknown whether adiponectin suppresses cold-induced thermogenesis though the IL-4–IL-13 pathway and alternative activation of macrophage, two well-known pathways...
downstream of ILC2 (Ding et al., 2016). Because expression levels of Penk are up-regulated by adiponectin deficiency in adipose tissue (Fig. 3 D), future studies will be needed to address whether Penk and IL-4–IL-13 pathways mediate the suppressive effect of adiponectin on thermogenesis. Up-regulation of leptin may also contribute to the defensive effect against obesity via ILC2 activation, given that leptin promotes the proliferation and activity of ILC2s in lung (Zheng et al., 2016; Zheng et al., 2018). In support of this, although adiponectin deficiency does not appear to overtly alter insulin sensitivity under normal chow diet conditions (Ma et al., 2002; Maeda et al., 2002), adiponectin has been reported to boost appetite, slow energy metabolism, and promote adipogenesis, all of which are well-defined factors promoting obesity development (Kubota et al., 2007; Kajimura et al., 2013; Kim et al., 2007). Similar to administration of peroxisome proliferator–activated protein γ agonists thiazolidinediones that improve insulin sensitivity but lead to severe obesity (Savage et al., 2003; Ristow et al., 1998), our study suggests that adiponectin-based treatment may bring the unfavorable effect of inducing obesity through inhibition of energy expenditure.

In summary, our study demonstrates that AMPK plays a critical role in regulating ILC2 function and adipose thermogenesis. AMPK interacts with the NF-κB pathway by serving as a target of TAK1 and a feedback regulator of downstream pathways of TAK1, such as IKKα/β and IkBa in ILC2s. Adiponectin suppresses ILC2 function via the AMPK pathway in vitro and in vivo. Cold stress down-regulates adiponectin, which alleviates AMPK-mediated feedback inhibition of IL-33 signaling and subsequently activates adipose-resident ILC2s and promotes adipose type 2 immune responses and thermogenesis. Therefore, our results reveal that adiponectin is a negative regulator of ILC2s through AMPK-dependent feedback inhibition of IL-33 signaling and that adiponectin exerts antithermogenic effects.

Materials and methods

Materials

Antibodies against phospho-AMPK (2531) at Thr272, AMPK (2603), phospho-IKKα (Ser180)/IKKβ (Ser177; 20785), IKKα (2682), IKKβ (2370), phospho-IκB at Ser32/36 (9246), IκBα (4814), phospho-ULK1 at Ser317 (6887), and ULK1 (8054) were from Cell Signaling. Anti-PGC1α (ST1204) was purchased from Millipore. Antibodies against AdipoR1 (ab126611), AdipoR2 (ab77612), UCP1 (ab23841), and C/EBPβ (ab32358) were from Abcam. Anti-ILC3B (L7543) from Sigma was used for Western blot, analysis and Anti-ILC3 pAb (PM036) from MBL International was used for staining. Anti-adiponectin and anti-β-tubulin were kindly provided by Dr. Lily Dong (University of Texas Health Science Center at San Antonio, San Antonio, TX) as described previously (Alsted et al., 2009; Meng et al., 2017). AdipoRon (924416-43-3) and SZ (253863-19-3) were obtained from Cayman Chemical Company. IRAK 1/4 inhibitor I (Is0409) and rapamycin (R8781) were from Sigma-Aldrich. 3-MA (189490) was purchased from EMD Millipore. Two recombinant mouse adiponectin (full-length and mutated C39A) proteins (ab62957 and ab94676) were purchased from Abcam. Mouse ST2/IL-1 R4 antibody (MAB10041) was from R&D Systems.

Mice

All mice used in this study were males unless specified otherwise. Adiponectin knockout mice were kindly provided by Dr. Philipp Scherer (University of Texas Southwestern Medical Center, Dallas, TX). This mouse line was crossed with C57BL/6J (stock no. 000664) for >10 generations before the study began. Both Rag2 KO mice (stock no. 008449) and Il2rg KO mice (stock no. 003174) with C57BL/6J background were purchased from Jackson Laboratory. We generated Rag2/Ii2rg double-KO mice by crossing the Rag2 KO mice and Ii2rg KO mice and then in-breeding the resulting Rag2/Ii2rg heterozygous offspring. Another stain of adiponectin-deficient mouse was ordered from Jackson Laboratory (B6;129-Adipoqtm1Chan/J, stock no. 008195; Adipo-) and backcrossed with C57BL/6 mice for four generations to validate the antithermogenic function of adiponectin. All animals were housed in a pathogen-free barrier facility with a 12-h light/12-h dark cycle with free access to food and water. All animal experimental protocols were reviewed and approved by the Animal Care Committee of the University of New Mexico Health Sciences Center. For cold stress studies, the mice were housed in an environmental chamber at 30°C followed by 48 h of either 22°C or 6°C and then euthanized for Western blot analysis, as described in our previous study (Ding et al., 2016; Wang et al., 2018).

Isolation and treatment of adipose tissue ILC2s

SVFs were isolated from subcutaneous and epididymal white fat of 2–3-mo-old male mice and then blocked with fragment crystallizable region-block (home-made) at 4°C for 20 min. For the signaling study of ILC2s, F4/80+, Gr-1+, and CD3+ cells were depleted using the indicated antibodies and magnetic beads. Cells were then incubated with ST2 antibody, and ST2+ cells were pulled down by loading the tube onto the magnetic rack (Invitrogen) for 5 min. Cell pellets were suspended in medium containing RPMI 1640 and 1% FBS for the following treatment. For the signaling study, there were the following three types of treatment: (i) cells were treated with 10 ng/ml IL-33 only for 10 min; (ii) cells were treated with 10 μM AdipoRon or 5 μg/ml full-length adiponectin for 1 h, followed by cotreatment with IL-33 for 10 min; and (iii) cells were treated with 1 μM AMPK inhibitor compound C for 20 min, followed with cotreatment with IL-33 for 20 min. The phosphorylation of IKKα/β, IκBα, or AMPK was determined using flow cytometry with specific antibodies. For the ELISA analysis, fragment crystallizable region-blocked SVF cells were washed and stained with anti-CD45-PE, anti-LC3-APC, and anti-IL-4-FITC for 10 min on ice. Then, live CD45−Lin−ST2+ ILC2s were sorted-purified by a Sony iCyt SY3200 four-laser cell sorter to 95% purity, and 10⁴ cells were harvested in TriZol buffer. For the measurement of IL-13 secretion, ILC2s or SVFs were cultured in the medium containing 10% FBS and treated with 5 μg/ml full-length adiponectin or 1 μM compound C for 1 h followed by cotreatment with IL-33 for 18 h, and media was collected for ELISA analysis.

Primary culture and differentiation of Th2 cells

CD45R−CD8α−CD62L− naive T cells were isolated from lymph nodes and spleens in 2–3-mo-old C57BL/6 WT mice using beads.
Cells were then seeded on a plate coated with α-CD3/α-CD28 and differentiated into Th2 cells using a RPMI medium containing 10% FBS, 5 μg/ml anti-IFNy, and 10 ng/ml IL-4 for 72 h. To suppress TAK1 and AMPK in differentiated Th2 cells, siRNA of TAK1 or siRNA of AMPKa1/2 and the control siRNA were introduced into Th2 cells using electroporation with Neon transfection system (1,600 V, 10 ms/pulse, three pulses). 30 h after transfection, TAK1-suppressed and scramble cells were cultured in a fresh RPMI medium with 1% FBS for 1 h and then treated with or without 10 ng/ml IL-33 for 10 min. To determine the role of AMPK in regulating IL-33 signaling, AMPK-suppressed and scramble cells were cultured in a fresh RPMI medium with 1% FBS for 1 h and then treated with (i) 10 ng/ml IL-33 only for 10 min; (2) 10 μM AdipoRon or 5 μg/ml full-length adiponectin for 1 h, followed by cotreatment with IL-33 for 10 min; or (3) 1 μM AMPK inhibitor compound C for 20 min, followed by cotreatment with IL-33 for 20 min. In addition, starved Th2 cells were treated with 10 ng/ml IL-33 only for 10 min, 10 μM AdipoRon, or 5 μg/ml full-length adiponectin for 1 h, followed by cotreatment with IL-33 for 10 min or 1 μM AMPK inhibitor compound C for 20 min and cotreatment with IL-33 for 20 min.

**ELISA analysis of IL-13 and IL-4**

For the measurement of IL-13 and IL-4 secretion, SVFs from adipose tissue were cultured in FBS-free medium containing 0.5% BSA and then treated with or without 5 μg/ml full-length adiponectin for 1 h followed by treatment with or without 10 ng/ml IL-33 for 18 h. The media was collected for ELISA analysis of IL-13 and IL-4. The ELISA assay for IL-13 or IL-4 from ILC2s and/or SVFs was determined using an ELISA kit (R&D Systems) according to the manufacturer’s protocol.

**Proliferation and cell death assay of ILC2s**

For the proliferation assay, epididymal fat samples from 7-wk-old adiponectin WT and KO mice were dissected, minced, digested with collagenase A (Roche), and filtered with 70 μm cell strainer (Falcon). The SVF were isolated and fixed with 4% polyformaldehyde at 4°C for 15 min. Ki67 expression in ILC2s was measured by intracellular staining on a CD45+Lin α-CD28 and the control α-CD28 antibody were in ipsilateral administration, TAK1-suppressed and scramble cells were cultured in a fresh RPMI medium with 1% FBS for 1 h and then treated with (i) 10 ng/ml IL-33 only for 10 min; (2) 10 μM AdipoRon or 5 μg/ml full-length adiponectin for 1 h, followed by cotreatment with IL-33 for 10 min; or (3) 1 μM AMPK inhibitor compound C for 20 min, followed by cotreatment with IL-33 for 20 min. In addition, starved Th2 cells were treated with 10 ng/ml IL-33 only for 10 min, 10 μM AdipoRon, or 5 μg/ml full-length adiponectin for 1 h, followed by cotreatment with IL-33 for 10 min or 1 μM AMPK inhibitor compound C for 20 min and cotreatment with IL-33 for 20 min.

**Adiponectin or AdipoRon administration**

For i.p. administration, AdipoRon was dissolved in DMSO and diluted by vehicle solution, which contained 5% Tween 80 and 5% polyethylene glycol 400 in PBS. 10-wk-old adiponectin KO male mice were administered with AdipoRon or vehicle by i.p. injection at 30 mg/kg body weight once a day for 5 d. 24 h after the first administration, the calorimetry study was performed. The mice were euthanized after 48 h of cold conditions, and fat tissues were harvested for Western blot analysis. For i.c.v. administration, 10-wk-old mice underwent cannula implantation surgery and recovered for 2 wk. 2 μl trimeric (C39A) adiponectin (1 mg/ml) or vehicle was pumped into cerebral ventricle by micro syringe pump at the speed of 1 μl/minute. For the intra-iWAT administration, the procedure was performed on 10-wk-old mice as described in the previous study (Murphy et al., 2013). In brief, AdipoRon or vehicle (3 mg/kg body mass) was administered at five sites across the inguinal white adipose depot by a syringe equipped with a 30-gauge needle. Calorimetry studies were performed at 6°C, after i.c.v. or intra-iWAT injection, and fat tissues were harvested for Western blot analysis.

**Administration of IL-33 receptor antibody**

10-wk-old male adiponectin WT and KO mice were administered with or without mouse ST2/IL-1 R4 antibody (R&D Systems) at 100 μg/mice/day by i.p. injection under cold exposure (6°C) for 2 d. The mice were euthanized, and adipose tissues were collected for flow cytometry analysis and Western blot analysis.

**Flow cytometry**

The suspended SVFs from adipose depots of 10-wk-old male mice were fixed, blocked, and stained with conjugated antibodies, including anti-CD45, anti-Siglec-5, anti-CD11b, and anti-CD206 (eBioscience and BioLegend), to identify macrophage subsets. To detect ILC2s (CD45^-Lin^-CD90.2^+ST2^+^), SVF cells were incubated with conjugated anti-CD45, anti-Lin (CD9e, CD11b, B220, CD11c, and Gr-1), anti-CD90.2, and anti-ST2 (eBioscience and BioLegend) after fixation unless specified otherwise. In Fig. S1 D, we used additional markers, including anti-RORC and anti-GATA3 (eBioscience), to gate ILC2s (CD45^-Lin^-CD90.2^+RORC^-ST2^-GATA3^-). Anti-AMPK α 1 (phospho-T183) and AMPK α 2 (phospho-T172) antibody (ab23875; Abcam), eFluor 660-conjugated anti-phospho-IκBα (S32/S36; eBioscience), and PE-conjugated phospho-IKKα/β (Ser176/180; Cell Signaling) were used to detect phospho-AMPK, phospho-IκBα and phospho-IKK in ILC2. For the staining of GATA3, RORC and phosphorylated proteins, cells were permeabilized with 0.25% Triton X-100 for 20 min after fixation. FACS analysis was performed on a FACS Calibur (BD PharMingen), and the data were analyzed with FlowJo software as described previously (Dong et al., 2013). The gating strategy used for ILC2s, eosinophils, and macrophages in adipose tissue is shown in Fig. S3, I-K.

**Energy expenditure**

10-wk-old male mice were individually housed in eight separate Promethion Metabolic Phenotyping Systems (Sable Systems International) coupled with a temperature controllable chamber. O2 consumption, carbon dioxide release, food intake, water intake, and the activity of each animal were monitored at room temperature (22°C) for 72 h and then in cold stress conditions (6°C) for 48 h. The data were analyzed using the ExpeData software associated with the system. O2 consumption was normalized by body weight as we described previously (Luo et al., 2017; Zhang et al., 2018).

**Telemetry study**

The Mini-Mitter Telemetry System was used for the measurement of core body temperature in adiponectin KO and WT mice.
as we described previously (Liu et al., 2014). Briefly, a Mini-Mitter implantable biotelemetric thermosensor was surgically implanted into the peritoneal cavity of 10-wk-old male mice. 10 d after surgery, mice were individually housed in the cage with free access to food and water at room temperature (22°C) for 12 h (8 a.m. to 8 p.m.) followed by exposure to cold stress (6°C) for 12 h (8 p.m. to 8 a.m.). The body temperature and locomotor activity were recorded every 5 min and analyzed with VitalView software.

**Western blot**

For tissue samples, frozen samples of BAT were sliced and ~1 mg tissue sample was homogenized for Western blot analysis. For the iWAT samples, tissue samples around the lymph node in the inguinal fat was used for the Western blot considering that UC1P1 cells are predominantly in the inguinal region rather than the dorsolumbar region after a 2-d cold exposure within a posterior subcutaneous fat pad (Chi et al., 2018). Cell lysates were prepared in ice-cold lysis buffer, and the general procedures were used for Western blot as described in our previous study (Liu et al., 2008). For all Western blot data presented in this study, the x axis indicates the individual mouse or the individual cell treatment.

**Induction of allergic asthma**

For induction of allergic asthma, age-matched adiponectin KO and WT male littermates were immunized intranasally with For all Western blot data presented in this study, the x axis in- volveolar lavage fluids (BALFs) were collected for analysis of airway inflammation of LLNs from asthmatic mice were prepared, and Ki67 expression was measured in Th2 cells (Lin−CD4+GATA3−), ILC2s (Lin−CD4+GATA3+), and Th1 cells (Lin−CD4+IFNy+). Lineage markers include CD3, CD5, B220, CD11b, CD11c, Gr-1, Ter119, and IgE. Antibodies to CD3, CD5, B220, CD11b, CD11c, Gr-1, Ter119, IgE, CD4, GATA3, IFNy, and Ki67 were purchased from eBioscience.

**Statistics**

Effects of various treatments on the expression levels of nor- epinephrine and UC1P1 in cells were analyzed by t test for comparison of two groups or one-way ANOVA for comparison of more than two groups. ANOVA was used for the statistical analysis of energy expenditure. For each group, 5–10 animals were used for in vivo experiments. The individual in vitro experiment was repeated at least three times. Data are presented as means ± SEM. P < 0.05 was considered as significant.

**Online supplemental material**

Fig. S1 shows that adiponectin deficiency promotes a type 2 immune response in adipose tissue and allergic airway. Fig. S2 indicates that adiponectin inhibits thermogenesis in a peripheral tissue–dependent manner. Fig. S3 demonstrates that adiponectin KO also increases O2 consumption and up-regulates thermogenic gene expression and ILC2 activation in adipose tissue of another mouse model and describes the gating strategy used for flow cytometric analysis in adipose tissue.

**Acknowledgments**

We acknowledge the National Institute of Diabetes and Digestive and Kidney Diseases, American Diabetes Association, the National Institute of General Medical Science, American Heart Association, and University of New Mexico Health Sciences Center (UNM-HSC) for the funding support. We thank the University of New Mexico Comprehensive Cancer Center for providing the FACs Calibur and Sony iCyt ST3200 four-laser cell sorter for the present study. We also thank Chaselyn Ruffian-Hanson and Lily Elizabeth Feldman at the University of New Mexico Health Sciences Center for proofreading the manuscript. This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R01 award DK110439 to M. Liu), the American Diabetes Association (Innovative Basic Science Award 1-17-IBS-261 to M. Liu), the American Heart Association (Grant in Aid Award I5GRNT24940018 to M. Liu and P20 Award GM121176 to Vojo Deretic, M. Liu, and X.O. Yang), and the University of New Mexico Health Sciences Center (Center of Biologic Research Excellence pilot award P30GM103400 to Ke Jian ’Jim’ Liu and M. Liu; R21 award AI142200 to X.O. Yang; CVMD pilot award to M. Liu; Clinical and Translational Science Center Pilot Award to M. Liu, and University of New Mexico Comprehensive Cancer Center pilot award to M. Liu). This project was supported in part by the University of New Mexico School of Medicine (Dedicated Health Research Funds).

Author contributions: M. Liu and X.O. Yang designed the project. L. Wang, Y. Luo, L. Luo, D. Wu, X. Ding, X. Yang, H. Zheng, F. Silva, X. Zhang, C. Wang, and X. Zheng conducted the experiments. L. Wang, Y. Luo, L. Luo, D. Wu, and X. Ding analyzed the results. J. Brimagi provided technical support on the i.c.v. injection of adiponectin. F. Liu, Z. Zhou, J. Chen, and M. Mandell were involved in the project discussions. M. Liu is guarantor of this work and wrote the manuscript. The manuscript was edited by X.O. Yang and F. Liu. H. Wu and B. Liu investigated the data. All authors reviewed and approved the manuscript.

Disclosures: The authors declare no competing interests exist.

Submitted: 11 June 2019
Revised: 20 October 2019
Accepted: 1 September 2020

**References**

Abbasi, F., J.W. Chu, C. Lamendola, T. McLaughlin, J. Hayden, G.M. Reaven, and P.D. Reaven. 2004. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes. 53:585–590. https://doi.org/10.2337/diabetes.53.3.585

Ahima, R.S. 2006. Metabolic actions of adipocyte hormones: focus on adiponectin. Obesity (Silver Spring). 14(2S, Suppl 1):9S–15S. https://doi.org/10.1038/oby.2006.276
Duran, A., J.F. Linares, A.S. Galvez, K. Wikenheiser, J.M. Flores, M.T. Diaz-Dong, M., X. Yang, S. Lim, Z. Cao, J. Honek, H. Lu, C. Zhang, T. Seki, K. Carling, D. 2004. The AMP-activated protein kinase cascade--a unifying system for energy control. J. Physiol. 288: R1220–R1225. https://doi.org/10.1126/japi.ajp0912.2004

Ali, S., A. Mohs, M. Thomas, J. Klare, R. Ross, M.L. Schmitz, and U.M. Martin. 2011. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J. Immunol. 187:1609–1616. https://doi.org/10.4049/jimmunol.0903808

Alsted, T.J., L. Nybo, M. Schweiger, C. Fleideli, P. Jacobsen, R. Zimmermann, R. Kliens. 2009. Adipose triglyceride lipase in human skeletal muscle is upregulated by exercise training. Am. J. Physiol. Endocrinol. Metab. 296:E445–E453. https://doi.org/10.1152/ajpendo.90091.2008

Antonia, R.J., and A.S. Baldwin. 2018. IKK promotes cytokine-induced and cancer-associated AMPK activity and attenuates phenformin-induced cell death in LKB1-deficient cells. Sci. Signal. 11:eaam5850. https://doi.org/10.1126/scisignal.esc8200

Awazawa, M., K. Ueki, K. Inabe, T. Yamauchi, K. Kubo, K. Nakano, M. Kobayashi, A. Iwane, T. Sasaki, Y. Okazaki, et al. 2011. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 13:401-412. https://doi.org/10.1016/j.cmet.2011.02.010

Bauch, L.B., S.A. El Miradem, A.M. Pottier, M. Senou, M.C. Many, R. Rezsohazy, L. Penicaud, N. Maeda, T. Funahashi, and S.M. Brichard. 2007. UCP1 mediates the mitigating effect of cold exposure on atherosclerotic plaque growth and instability via UCP1-dependent lipolysis. Cell Metab. 5:212-227. doi.org/10.1016/j.cmet.2007.02.004

Blagih, J., F. Coulombe, E.E. Vincent, F. Dupuy, G. Galicia-Vázquez, E. Yudayko, T.C. Raissi, G.J. van der Windt, B. Viollet, E.L. Pearce, et al. 2015. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity. 42:41–54. https://doi.org/10.1016/j.immuni.2014.12.030

Boström, P., J. Wu, M.P. Jeychowsky, A. Korde, L.Y, J.C. Lo, K.A. Rasbach, E.A. Boström, J.H. Choi, J.Z. Long, et al. 2012. A PGC-1α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 481:463-468. https://doi.org/10.1038/nature10779

Brestoff, J.R., B.S. Kim, S.A. Saenz, R.R. Stine, L.A. Monticelli, G.F. Sonnenberg, J.J. Thome, D.L. Farber, K. Lutfi, P. Seale, and D. Artis. 2015. Group 2 innate lymphoid cells promote browning of white adipose tissue and limit obesity. Nature 519:242-246. https://doi.org/10.1038/nature14115

Cao, Z., J. Xiong, M. Takeuchi, T. Kurama, and D.V. Goeddel. 1996. TRAF6 is a signal transducer for interleukin-1. Nature. 383:445-446. https://doi.org/10.1038/383445a0

Carling, D. 2004. The AMP-activated protein kinase cascade—a unifying system for energy control. Trends Biochem. Sci. 29:18–24. https://doi.org/10.1016/j.tibs.2003.11.005

Cayrol, C., and J.P. Girard. 2014. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr. Opin. Immunol. 31:1-37. https://doi.org/10.1016/j.coi.2014.09.004

Chen, Z., X. Shen, F. Shen, W. Zhong, H. Wu, S. Liu, and J. Lai. 2013. TAK1 activates AMPK-dependent cell death pathway in hydrogen peroxide-treated cardiomyocytes, inhibited by heat shock protein-70. Mol. Cell. Biochem. 375:35–44. https://doi.org/10.1007/s11010-013-1568-z

Cheng, X., E.J. Folco, K. Shimizu, and P. Libby. 2012. Adiponectin induces pro-inflammatory programs in human macrophages and CD4 T cells. J. Biol. Chem. 287:36896–36904. doi.org/10.1074/jbc.M112.409516

Chi, J., Z. Wu, C.H.J. Choi, L. Nguyen, S. Teggegan, S.E. Ackerman, A. Crane, F. Marchildon, M. Tessier-Lavigne, and P. Cohen. 2018. Three-Dimensional Adipose Tissue imaging Reveals Regional Variation in Beige Fat Biogenesis and PPARγ-Mediated Dependent Neurite Density. Cell Metab. 27:226–236.e3. https://doi.org/10.1016/j.cmet.2017.12.011

Coleman, D.L., and K.P. Hummel. 1973. The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-Ks and C57BL-6j strains. Biochem. Genet. 7:1–15. https://doi.org/10.1007/BF00487005

Kadowaki, T., and T. Yamauchi. 2005. Adiponectin and adiponectin receptors. Endocr. Rev. 26:439–451. https://doi.org/10.1210/er.2012.005-0005

Kajimura, D., H.W. Lee, K.J. Riley, E. Arteaga-Solis, M. Ferron, B. Zhou, C.J. Clarke, Y.A. Hannun, R.A. DePinho, X.E. Guo, et al. 2013. Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab. 17:901–915. https://doi.org/10.1016/j.cmet.2013.08.009

Kim, J.Y., E. van de Wall, M. Laplante, A. Azzara, M.E. Trujillo, S.M. Hofmann, T. Schraw, J.L. Durand, H. Li, G. Li, et al. 2007. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117:2621–2637. https://doi.org/10.1172/JCI31021

Kolodin, D., N. van Panhuys, C. Li, A.M. Magnuson, D. Cipolletta, C.M. Miller, A. Wagers, R.N. Germain, C. Benoist, and D. Mathis. 2015. Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metab. 21:543–557. https://doi.org/10.1016/j.cmet.2015.04.007

Koyasu, S., and K. Muro. 2013. Th2-type innate immune responses mediated by natural helper cells. Ann. N. Y. Acad. Sci. 1283:43–49. https://doi.org/10.1111/j.1497-5618.2012.12016.x

Kubota, N., W. Yano, T. Kubota, T. Yamauchi, S. Itoh, H. Kugamai, H. Kozono, I. Takamoto, S. Okamoto, T. Shiuchi, et al. 2007. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. J. Cell. Physiol. 213:55–68. https://doi.org/10.1002/jcp.20704

Kumada, M., S. Kihara, N. Ouchi, H. Kobayashi, Y. Okamoto, K. Ohashi, K. Maeda, H. Nagaretani, K. Kishida, N. Maeda, et al. 2004. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 109:2046–2049. https://doi.org/10.1161/01.CIR.0000127953.98131.ED

Kuwanto, W., D. Burzyn, M. Panduro, K.C. Wang, Y.C. Jang, A.J. Wagers, C. Benoist, and D. Mathis. 2016. Poor Repair of Skeletal Muscle in Aging

Wang et al. Adiponectin inhibits IL2C function. Journal of Experimental Medicine. 2019.1054.
Mice Reflects A Defect in Local, Interleukin-33-Dependent Accumula-
tion of Regulatory T Cells. Immunity. 44:355–367. https://doi.org/10.
1016/j.imm.2019.01.009

Lallena, M.J., M.T. Diaz-Meco, G. Boren, C.V. Payá, and J. Moscat. 1999. Ac-
tivation of IkappaB kinase beta by protein kinase C isoforms. Mol. Cell.
Biol. 19:2180–2188. https://doi.org/10.1128/MCB.19.3.2180

Lee, M.W., J.I. Odegaard, L. Mukundan, Y. Qiu, A.B. Molofsky, J.C. Nussbaum,
K. Yun, R.M. Locksley, and A. Chawla. 2015. Activated type 2 innate lymphoid
cells regulate beige fat biogenesis. Cell. 160:74–87. https://doi.org/10.
1016/j.cell.2014.12.011

Lei, A.H., Q. Xiao, G.Y. Liu, K. Shi, Q. Yang, X. Li, Y.F. Liu, H.K. Wang, W.P.
Cai, Y.J. Guan, et al. 2018. ICAM-1 controls development and function of 
ILC2. J. Exp. Med. 215:2157–2174. https://doi.org/10.1084/jem.20172359

Li, Q., D. Li, X. Zhang, Q. Wan, W. Zhang, M. Zheng, L. Zou, C., J.H. Lee, and 
Y.C. Liu. 2018. E3 Ligase VHL Promotes Group 2 Innate Lymphoid Cell 
Maturation and Function via Glycolysis Inhibition and Induction of 
Interleukin-33 Receptor. Immunity. 48:258–270.e5. https://doi.org/10.
1016/j.imm.2017.12.013

Licona-Limón, P., L.K. Kim, N.W. Palm, and R.A. Flavell. 2013. Th2, allergy 
and group 2 innate lymphoid cells. Nat. Immunol. 14:536–542. https://
doi.org/10.1038/ni.2617

Liu, M., Z. Zhou, A. Xu, K.S. Lam, M.D. Wetzal, R. Xiang, J. Zhang, X. Yin, L.Q.
Dong, and F. Liu. 2008. A disulfide-bond A oxidoreductase-like protein 
(DaA1) regulates adiponectin multimerization. Proc. Natl. Acad. Sci.
U.S.A. 105:18302–18307. https://doi.org/10.1073/pnas.0806341105

Liu, M., J. Bai, S. He, R. Villarreal, D. Hu, C. Zhang, X. Yang, H. Liang, T.J. 
Slaga, Y. Yu, et al. 2014. Grib10 promotes lipolysis and thermogenesis by 
phosphorylation-dependent feedback inhibition of mTORC1. Cell Metab.
19:927–930. https://doi.org/10.1016/j.cmet.2014.03.018

Liu, W., Y. Jiang, J. Sun, S. Geng, Z. Pan, H.A. Prinz, C. Wang, J. Sun, X. jiao, 
and X. Xu. 2018. Activation of TGF-β-activated kinase 1 (TAK1) restricts 
Salmonella Typhimurium growth by inducing AMPK activation and autophagy.
Cell Death Dis. 9:570. https://doi.org/10.1038/s41419-018-0621-2

Lloyd, C.M. 2010. IL-33 family members and asthma - bridging innate and 
acquired immunity. J. Biol. Chem. 285:7153–7160. https://doi.org/10.
1074/jbc.E110.107753

Long, Y.C., and J.R. Zierath. 2006. AMP-activated protein kinase signaling in 
muscle regulation. J. Clin. Invest. 116:1776–1783. https://doi.org/10.
1172/JC29044

Luo, Y., B. Liu, X. Yang, X. Ma, X. Zhang, D.E. Bragin, X.O. Yang, W. Huang, 
and M. Liu. 2017. Myeloid adrenergic signaling via CaMKII forms a 
feedforward loop of catecholamine biosynthesis. J. Mol. Cell Biol. 9:
422–434. https://doi.org/10.1016/j.molcel.2017.09.046

Ma, K., A. Cabrero, P.K. Saha, H. Kojima, L. Li, B.H. Chang, A. Paul, and L.
Chan. 2002. Increased beta -oxidation but no insulin resistance or 
glucose intolerance in mice lacking adiponectin. Am. J. Physiol. Endocrinol.
Metab. 283:E1347–E1357. https://doi.org/10.1152/ajpendo.00021.2013

Okada-Iwabu, M., T. Yamauchi, M. Iwabu, T. Homma, K. Hamagami, K.
Matsuda, M. Yamaguchi, H. Tanabe, T. Kimura-Someya, M. Shirozu, et 
al. 2013. A small-molecule AdipoR agonist for type 2 diabetes and 
short life in obesity. Nature. 503:493–499. https://doi.org/10.1038/
nature12656

Oldenhove, G., E. Boucquy, A. Taquin, V. Acolty, L. Bonetti, B. Ryffel, M.
Bert, K. Englebert, L. Boon, and M. Moser. 2018. PD-1 Is Involved in the 
Dysregulation of Type 2 In innate Lymphoid Cells in a Murine Model of 
Obesity. Cell Rep. 25:2053–2060.e4. https://doi.org/10.1016/j.celrep.
2018.10.091

Park, P.H., K.R. McMullen, H. Huang, V. Thakur, and L.E. Nagy. 2007. Short-
term treatment of RAW264.7 macrophages with adiponectin increases 
tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activa-
tion and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated 
macrophage activation and differentiation. J. Biol. Chem. 282:21965–219703.
https://doi.org/10.1074/jbc.M701419200

Petrovic, N., J.B. Gallo, I.G. Shabalina, J.A. Timmons, B. Cannon, and J.
Nedergaard. 2010. Chronic peroxisome proliferator-activated receptor 
gamma agonists. J. Biol. Chem. 285:6155–6160. https://doi.org/10.
1074/jbc.M109.088708

Qi, Y., N. Takahashi, S.M. Hileman, H.R. Patel, A.H. Berg, U.B. Pajvani, P.E.
Newland, S.A., S. Mohanta, M. Clément, S. Taleb, J.A. Walker, M. Nus, A.P.
Sage, C. Yin, D. Hu, L.L. Kitt, et al. 2017. Type-2 innate lymphoid cells 
control the development of atherosclerosis in mice. Nat. Commun. 8:
15781. https://doi.org/10.1038/s41467-017-00858

Qi, Y., N. Takahashi, S.M. Hileman, H.R. Patel, A.H. Berg, U.B. Pajvani, P.E.
Sage, C. Yin, D. Hu, L.L. Kitt, et al. 2017. Type-2 innate lymphoid cells 
control the development of atherosclerosis in mice. Nat. Commun. 8:
15781. https://doi.org/10.1038/s41467-017-00858

Qi, Y., N. Takahashi, S.M. Hileman, H.R. Patel, A.H. Berg, U.B. Pajvani, P.E.
Sage, C. Yin, D. Hu, L.L. Kitt, et al. 2017. Type-2 innate lymphoid cells 
control the development of atherosclerosis in mice. Nat. Commun. 8:
15781. https://doi.org/10.1038/s41467-017-00858

Qi, Y., N. Takahashi, S.M. Hileman, H.R. Patel, A.H. Berg, U.B. Pajvani, P.E.
Sage, C. Yin, D. Hu, L.L. Kitt, et al. 2017. Type-2 innate lymphoid cells 
control the development of atherosclerosis in mice. Nat. Commun. 8:
15781. https://doi.org/10.1038/s41467-017-00858

Qi, Y., N. Takahashi, S.M. Hileman, H.R. Patel, A.H. Berg, U.B. Pajvani, P.E.
Sage, C. Yin, D. Hu, L.L. Kitt, et al. 2017. Type-2 innate lymphoid cells 
control the development of atherosclerosis in mice. Nat. Commun. 8:
15781. https://doi.org/10.1038/s41467-017-00858
Qiu, Y., K.D. Nguyen, J.I. Odegaard, X. Cui, X. Tian, R.M. Locksley, R.D. Palminter, and A. Chawla. 2014. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. J. Cell. 157:1292–1308. https://doi.org/10.1083/jcb.2014.03.066
Quaresma, P.G., N. Reenocber, T.M. Zanotto, A.C. Santos, L. Weissmann, A.H. de Matos, L. Lopes-Cendes, F. Polli, M.J. Saad, and P.O. Prada. 2016. Pioglitazone treatment increases food intake and decreases expenditure partially via hypothalamic adiponectin/adipoR1/AMPK pathway. Int. J. Obs. 40:138–146. https://doi.org/10.1038/ijo.2015.134
Rao, R.R., J.Z. Long, J.P. White, K.J. Svensson, J. Lou, I. Lokurkar, M.P. Je-Savage, D.B., G.D. Tan, C.L. Acerini, S.A. Jebb, M. Agostini, M. Gurnell, R.L. Quaresma, P.G., N. Reencober, T.M. Zanotto, A.C. Santos, L. Weissmann, A.H. Scherer, P.E. 2006. Adipose tissue: from lipid storage compartment to endocrine organ. J. Biol. Chem. 280:35625–35629. https://doi.org/10.1074/jbc.C500237200
Wu, X., H. Motoshima, K. Mahadev, T.J. Stalker, R. Scala, and B.J. Goldstein. 2003. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes. 52:1355–1363. https://doi.org/10.2337/diabetes.52.6.1355
Xie, M., D. Zhang, J.R. Dyck, Y. Li, H. Zhang, M. Morishima, D.L. Mann, G.E. Schranz, A. Neuhofer, B.K. Itariu, M. Keck, et al. 2013. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int. J. Obs. 37:658–665. https://doi.org/10.1016/j.ijobe.2012.118
Zhang, X., L. Luo, C. Wang, X. Ding, X. Yang, D. Wu, F. Silva, Z. Yang, Q. Zhou, L. Wang, et al. 2018. Adipose mTORC1 Suppresses Prostaglandin Signaling and Beige Adipogenesis via the CRTC2-COX-2 Pathway. Cell Rep. 24:3180–3193. https://doi.org/10.1016/j.celrep.2018.08.055
Zhang, H., G. Chen, J. Wang, et al. 2018. Leptin Promotes Allergic Airway Inflammation by Targeting the Unfolded Protein Response Pathway. J. Immunol. 199:5993–5999. https://doi.org/10.4049/jimmunol.1800556
Zheng, H., X. Zhang, E.F. Castillo, Y. Luo, M. Liu, and X.O. Yang. 2016. Leptin Enhances Th2 and IL-22 Responses in Allergic Airway Disease. J. Biol. Chem. 291:22043–22052. https://doi.org/10.1074/jbc.M115.700170
Zheng, H., D. Wu, X. Wu, X. Zhang, Q. Zhou, Y. Luo, X. Yang, C.J. Chock, M. Liu, and X.O. Yang. 2018. Leptin Promotes Allergic Airway Inflammation through Targeting the Unfolded Protein Response Pathway. Sci. Rep. 8:8905. https://doi.org/10.1038/s41598-018-2278-4
Zhu, J. 2015. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 75:14–24. https://doi.org/10.1016/j.cyto.2015.05.010
Figure S1. Adiponectin deficiency promotes type 2 immune response in adipose tissue and allergic airway. (A) Adiponectin receptor 1 and 2 (AdipoR1 and AdipoR2) were expressed in differentiated adipocytes (Adipo) and primary macrophages (MΦ). Representative data are presented from two independent experiments. (B) Adiponectin deficiency slightly increased the population of ILC2 (CD45+Lin−CD90.2+ST2+) in eWAT and iWAT, but not in BAT, at room temperature, while the difference in eWAT did not reach significance. n = 3/group. Data are presented as means ± SEM. *, P < 0.05, Student’s t test. (C) Adiponectin deficiency significantly increased the population of ILC2 (CD45+Lin−CD90.2+RORC−ST2+GATA3+) in brown (BAT), inguinal (iWAT), and epididymal (eWAT) at 6°C. n = 6/group. Data are presented as means ± SEM, *, P < 0.05, Student’s t test. (D) Adiponectin deficiency did not change the population of eosinophils (CD11b+Siglec-F+) in BAT, iWAT, and eWAT. n = 6/group. Data are presented as means ± SEM, *, P < 0.05, Student’s t test. (E) Adiponectin deficiency up-regulated mRNA levels of thermogenic markers UCP1 and type 2 cytokines such as IL-4 and IL-13 in BAT under both basal and cold stress conditions, although the up-regulation of IL-6 by adiponectin KO only occurred at room temperature condition, and the thermogenic marker PGC1α was only increased by adiponectin deficiency under cold stress conditions. n = 5–8/group. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01; Student’s t test. GAPDH was used as an internal control. For the following studies, 15 d after first-time immunization of adiponectin KO and WT mice with papain and OVA, BALFs and LLNs were collected for the analysis. (F) The intracellular stain of Ki67 in LLNs ILC2s from adiponectin KO and WT mice after induction of experimental asthma. n = 6/group. Data are presented as means ± SEM. Student’s t test. (G) Frequency of Th2 cells (TH2; Lin+CD4+IFNγ+) in LLNs cells from adiponectin KO and WT mice after induction of experimental asthma. n = 6/group. Data are presented as means ± SEM. Student’s t test. (H) The intracellular stain of GATA3 and IL-4 in LLNs cells from adiponectin KO and WT mice after induction of experimental asthma. n = 6/group. Data are presented as means ± SEM. Student’s t test. (I) The intracellular stain of GATA3 in LLNs cells from adiponectin KO and WT mice after induction of experimental asthma. n = 6/group. Data are presented as means ± SEM. Student’s t test. (J) The intracellular stain of IL-13 in LLNs cells from adiponectin KO and WT mice after induction of experimental asthma. n = 6/group. Data are presented as means ± SEM. Student’s t test. (K) The intracellular stain of IFNγ in LLNs cells from adiponectin KO and WT mice after induction of experimental asthma. n = 6/group. Data are presented as means ± SEM. Student’s t test. (L) The intracellular stain of IL-5 and IL-13 in LLNs cells from adiponectin KO and WT mice after induction of experimental asthma. n = 6/group. Data are presented as means ± SEM. Student’s t test. (M) The intracellular stain of IL-13 in LLNs cells from adiponectin KO and WT mice after induction of experimental asthma. n = 6/group. Data are presented as means ± SEM. Student’s t test. ADPN, adiponectin.
Figure S2. Adiponectin inhibits thermogenesis in a peripheral tissue-dependent manner. (A–D) For calorimetry analysis, mice were individually housed in the metabolic cages coupled with an environmental chamber. After 24-h adaptation at room temperature (22°C), the mouse was continuously housed in the system at 22°C for 48 h and then at 6°C for the times indicated. O₂ consumption, CO₂ release, food intake, body weight, water intake, break-beam activity, and wheel activity were monitored using the Sable International Phenotyping System. Given the difficulty in the balance of wheel activity and break-beam activity, the wheels were dissembled in the rest of studies. CO₂ release exhibited a same tenancy as O₂ consumption and was not included in the paper. The body composition (n = 4–5/group; A), food intake (n = 9/group; B), respiratory quotient (n = 9/group; C), and beam-break counts activity (n = 4/group; D) of adiponectin KO and WT mice at room temperature (22°C) and under cold stress condition (6°C) are shown. Data are presented as means ± SEM. Student’s t test.

(E) Locomotor activity of adiponectin KO and WT mice exposed to room temperature (22°C) and under cold stress conditions (6°C) with telemetry analysis. n = 4/group. Data are presented as means ± SEM. Student’s t test.

(F and G) The effect of AdipoRon administration on the food intake (F) and beam counts (G) of adiponectin KO and WT mice at room temperature (22°C) and under cold stress conditions (6°C). n = 7–9/group. Data are presented as means ± SEM. Student’s t test. (H and I) AdipoRon treatment suppressed the frequency of eosinophils (H) and macrophages (I) in iWAT, but not BAT, in adiponectin KO mice under cold stress conditions. n = 4–6/group. Data are presented as means ± SEM. Student’s t test. V, vehicle; A, AdipoRon. (J–L) O₂ consumption (J), food intake (K), and beam-break counts (L) of 10-wk-old male adiponectin KO mice that were administered with adiponectin by i.c.v. injection and housed at 22°C for 48 h and then at 6°C for 48 h. n = 7–9/group. Data are presented as means ± SEM. Student’s t test. ADPN, adiponectin; S, ST2 antibody.
Figure S3. Adiponectin KO increased O₂ consumption and up-regulated thermogenic gene expression and ILC2 activation in adipose tissue of another mouse model (B6;129-Adipoqtm1Chan/J mice from Jackson Laboratory that were backcrossed with C57BL/6 mouse for four generations).

(A–C) Adiponectin KO mice were individually housed for calorimetry analysis in the metabolic cages coupled with an environmental chamber. After 24-h adaptation at room temperature (22°C), mice were continuously housed in the system at 22°C for 48 h followed by cold exposure (6°C) for 48 h. O₂ consumption (A), beam-break activity (B) and food intake (C) were monitored at room temperature (22°C) and under cold stress conditions (6°C). The O₂ consumption data were normalized with body mass and analyzed by ANOVA. n = 7–8/group. Data are presented as means ± SEM. *, P < 0.05; Student’s t test.

(D–G) The expression levels of the thermogenic genes Ucp1 and C/ebpβ in both protein and mRNA were significantly up-regulated in iWAT (D and F) and BAT (E and G) by adiponectin deficiency under cold stress conditions. The mRNA levels of the ILC2 markers St2 and Penk, but not Il5, were significantly increased in iWAT (F) and BAT (G). n = 7–8/group. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01; Student’s t test. (H) The population of ILC2s was increased by adiponectin KO in iWAT despite no significant effect in BAT under cold stress conditions. n = 7–8/group. Data are presented as means ± SEM. *, P < 0.05. Student’s t test. For the flow cytometric analysis of adipose tissue, the gating strategy was summarized in the following figures (I–K).

The SVFs from adipose depots were isolated from 10-wk-old male mice and used for the flow cytometry analysis. (I) CD45+Lin–CD90.2+ST2+ cells were applied on ILC2s for Fig. 1, A, B, E, and F; Fig. 3, A and E; Fig. 5 D; Fig. 6 B; and Fig. S1 B. (J) CD45+Lin–CD90.2+RORC–ST22GATA3+ cells were applied on ILC2s for Fig. S1 C. (K) Eosinophils (CD45+CD11b+Siglec-F–), macrophages (CD45+CD11b+Siglec-F–), and M2 macrophages (CD45+CD11b+Siglec-F–CD206+) were differentiated in SVF of adipose tissue. ADPN, adiponectin; FSC-H, forward scatter-height; SSC-H, side scatter-height.